Cardiovascular risks associated with dipeptidyl peptidase‐4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study
- 23 July 2019
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (9) , 1166-1174
Abstract
Purpose: We evaluated the cardiovascular risk associated with dipeptidyl peptidase‐4 inhibitors (DPP‐4Is) as monotherapy compared with other antidiabetic drugs in Japan.Methods: We conducted a nationwide cohort study involving 2 716 000 diabetes patients in Japan. New users of any antidiabetic drug as monotherapy between 1 April 2010 and 31 October 2014 were identified. Occurrences of myocardial infarction (MI), heart failure (HF), and stroke requiring hospitalization associated with DPP‐4Is were compared with those associated with biguanides (BGs), sulfonylureas (SUs), or α‐glucosidase inhibitors (α‐GIs). Adjusted hazard ratios (aHRs) for these outcomes were estimated by Cox proportional hazards model. Propensity score standardization was used to control for confounding.Results: We identified 1 105 103 patients using DPP‐4Is, 278 280 patients using BGs, 273 449 patients using SUs, and 217 026 patients using α‐GIs. The risks of MI and HF for DPP‐4I users were significantly higher than those for BG users (MI: aHR, 1.48 [95%CI, 1.20‐1.82], HF: aHR, 1.46 [95%CI, 1.31‐1.62]), while significantly lower than those for SU users (MI: aHR, 0.84 [95%CI, 0.72‐0.98], HF: aHR, 0.86 [95%CI, 0.81‐0.92]). The risk of MI for DPP‐4I users was similar to that for α‐GI users, while the risk of HF for DPP‐4I users was slightly higher than for α‐GI users (MI: aHR, 0.98 [95%CI, 0.82‐1.17], HF: aHR, 1.12[95%CI, 1.04‐1.21]).Conclusions: Risk of MI and HF requiring hospitalization associated with DPP‐4Is as monotherapy was significantly higher than BGs, significantly lower than SUs, and similar to α‐GIs.Keywords
This publication has 26 references indexed in Scilit:
- Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic DrugsAnnals of Internal Medicine, 2016
- Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal studyCardiovascular Diabetology, 2016
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2015
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesNew England Journal of Medicine, 2013
- Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2013
- Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2012
- Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative reviewDiabetes, Obesity and Metabolism, 2010
- Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes populationDiabetes, Obesity and Metabolism, 2010
- Diabetes and AtherosclerosisJAMA, 2002